MoonLake Immunotherapeutics Insider Trading
MLTX
Insiders sold $83M and bought nothing on the open market.
14% of the selling was scheduled in advance under 10b5-1 plans. Director Mark N Lampert sold $63M on Mar 31, 78% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2025.
Get an email when MLTX's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jul 27 | Kristian Reich Chief Scientific Officer | Sold10b5-1 plan | 1,100 | $20.00 | 22K | <0.1% | Form 4 |
| Jul 21 – 22 | Kristian Reich Chief Scientific Officer | Sold10b5-1 plan 2 parts | 52,448 | $20.02 average | $1.05M | 1.9% | Form 4 |
| Jul 20 | Kristian Reich Chief Scientific Officer | Sold10b5-1 plan | 43,700 | $20.09 | 878K | 1.5% | Form 4 |
| Jul 15 | Kristian Reich Chief Scientific Officer | Sold10b5-1 plan | 16,105 | $20.01 | 322K | 0.6% | Form 4 |
| Jul 9 – 10 | Da Silva Jorge Santos Chief Executive Officer | Sold10b5-1 plan 2 parts | 102,225 | $20.02 average | $2.05M | 3.6% | Form 4 |
| Jul 1 | Da Silva Jorge Santos Chief Executive Officer | Sold10b5-1 plan | 47,775 | $20.03 | 957K | 1.6% | Form 4 |
| Jun 22 | Matthias Bodenstedt Chief Financial Officer | Sold10b5-1 plan | 39,120 | $22.04 | 862K | 3.4% | Form 4 |
| Jun 17 – 18 | Matthias Bodenstedt Chief Financial Officer | Sold10b5-1 plan 2 parts | 17,876 | $19.67 average | 352K | 1.5% | Form 4 |
| Jun 15 – 17 | Kristian Reich Chief Scientific Officer | Sold10b5-1 plan 3 parts | 150,000 | $19.01 average | $2.85M | 5.0% | Form 4 |
| May 11 | Matthias Bodenstedt Chief Financial Officer | Sold10b5-1 plan | 13,653 | $20.02 | 273K | 1.2% | Form 4 |
| Apr 14 | Matthias Bodenstedt Chief Financial Officer | Sold10b5-1 plan | 2,426 | $19.56 | 47K | 0.2% | Form 4 |
| Apr 10 – 13 | Da Silva Jorge Santos Chief Executive Officer | SoldNo plan 2 parts | 150,000 | $18.35 average | $2.75M | 4.9% | Form 4 |
| Apr 9 – 10 | Matthias Bodenstedt Chief Financial Officer | Sold10b5-1 plan 2 parts | 87,795 | $18.95 average | $1.66M | 6.9% | Form 4 |
| Mar 31 | Mark N Lampert Director | SoldNo plan 3 parts | 3,750,000 | $16.79 average | $63M | 78% | Form 4 |
| Dec 8, 2025 – Dec 9, 2025 | Da Silva Jorge Santos Chief Executive Officer | SoldNo plan 2 parts | 200,000 | $14.87 average | $2.97M | 6.5% | Form 4 |
| Dec 8, 2025 – Dec 9, 2025 | Kristian Reich Chief Scientific Officer | SoldNo plan 2 parts | 202,908 | $14.85 average | $3.01M | 6.4% | Form 4 |
| Oct 8, 2025 | Matthias Bodenstedt Chief Financial Officer | Bought | 10,870 | $9.09 | 99K | 1.8% | Form 4 |
| Sep 29, 2025 – Sep 30, 2025 | Cormorant Global Healthcare Master Fund, LP Large holder | SoldNo plan 5 parts | 6,499,978 | $7.21 average | $46.9M | 77% | Form 4 |
| Jul 3, 2025 | Catherine Moukheibir Director | SoldNo plan | 23,500 | $48.79 | $1.15M | 100% | Form 4 |
- Jul 2710b5-1 planKristian ReichChief Scientific Officer · sold 1,100 at $20.0022K<0.1% of stake
- Jul 21 – 2210b5-1 planKristian ReichChief Scientific Officer · sold 52,448 at avg $20.02$1.05M1.9% of stake
- Jul 2010b5-1 planKristian ReichChief Scientific Officer · sold 43,700 at $20.09878K1.5% of stake
- Jul 1510b5-1 planKristian ReichChief Scientific Officer · sold 16,105 at $20.01322K0.6% of stake
- Jul 9 – 1010b5-1 planDa Silva Jorge SantosChief Executive Officer · sold 102,225 at avg $20.02$2.05M3.6% of stake
- Jul 110b5-1 planDa Silva Jorge SantosChief Executive Officer · sold 47,775 at $20.03957K1.6% of stake
- Jun 2210b5-1 planMatthias BodenstedtChief Financial Officer · sold 39,120 at $22.04862K3.4% of stake
- Jun 17 – 1810b5-1 planMatthias BodenstedtChief Financial Officer · sold 17,876 at avg $19.67352K1.5% of stake
- Jun 15 – 1710b5-1 planKristian ReichChief Scientific Officer · sold 150,000 at avg $19.01$2.85M5.0% of stake
- May 1110b5-1 planMatthias BodenstedtChief Financial Officer · sold 13,653 at $20.02273K1.2% of stake
- Apr 1410b5-1 planMatthias BodenstedtChief Financial Officer · sold 2,426 at $19.5647K0.2% of stake
- Apr 10 – 13No planDa Silva Jorge SantosChief Executive Officer · sold 150,000 at avg $18.35$2.75M4.9% of stake
- Apr 9 – 1010b5-1 planMatthias BodenstedtChief Financial Officer · sold 87,795 at avg $18.95$1.66M6.9% of stake
- Mar 31No planMark N LampertDirector · sold 3,750,000 at avg $16.79$63M78% of stake
- Dec 8, 2025 – Dec 9, 2025No planDa Silva Jorge SantosChief Executive Officer · sold 200,000 at avg $14.87$2.97M6.5% of stake
- Dec 8, 2025 – Dec 9, 2025No planKristian ReichChief Scientific Officer · sold 202,908 at avg $14.85$3.01M6.4% of stake
- Oct 8, 2025Matthias BodenstedtChief Financial Officer · bought 10,870 at $9.0999K1.8% of stake
- Sep 29, 2025 – Sep 30, 2025No planCormorant Global Healthcare Master Fund, LPLarge holder · sold 6,499,978 at avg $7.21$46.9M77% of stake
- Jul 3, 2025No planCatherine MoukheibirDirector · sold 23,500 at $48.79$1.15M100% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with MLTX
Held by ETFs
MLTX is in 14 US ETFs. The largest of them, with MLTX's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.00%of the fund
T. Rowe Price Capital Appreciation Equity ETFTCAF0.04%of the fund
Fidelity MSCI Health Care Index ETFFHLC0.01%of the fund
iShares ESG Aware MSCI USA Small-Cap ETFESML0.04%of the fund
Nuveen ESG Small-Cap ETFNUSC0.05%of the fund
Spot a number that looks wrong? Check it in MLTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MLTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.